Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

ABP

Abpro Holdings Inc

Feb 10 • 04:00PM ET

1.67

+0.15 9.87 %

Healthcare • Biotechnology • USA • NASD

Today, 4:22 AMProfit-taking reversed yesterday's rally triggered by Goldman Sachs' passive stake disclosure.

Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-12.45	Insider Own	36.26%	Shs Outstand	2.67M	Perf Week	-12.11%
Market Cap	4.54M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	1.73M	Perf Month	-58.66%
Enterprise Value	4.90M	PEG	-	EPS next Q	-	Inst Own	2.73%	Short Float	1.06%	Perf Quarter	-70.28%
Income	-22.04M	P/S	-	EPS this Y	-	Inst Trans	-14.59%	Short Ratio	0.01	Perf Half Y	-77.52%
Sales	0.00M	P/B	-	EPS next Y	-	ROA	-248.15%	Short Interest	0.02M	Perf YTD	-60.52%
Book/sh	-6.04	P/C	13.35	EPS next 5Y	-	ROE	-	52W High	34.65 -95.18%	Perf Year	-94.32%
Cash/sh	0.13	P/FCF	-	EPS past 3/5Y	-2359.24% -	ROIC	-	52W Low	1.44 15.97%	Perf 3Y	-99.46%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	24.94% 17.64%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-95.93%	Oper. Margin	-	ATR (14)	0.43	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	0.07	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	26.66	Recom	3.00
Dividend Gr. 3/5Y	- -	Current Ratio	0.07	EPS Q/Q	48.60%	SMA20	-31.92%	Beta	0.00	Target Price	60.00
Payout	-	Debt/Eq	-	Sales Q/Q	-	SMA50	-58.71%	Rel Volume	289.71	Prev Close	1.52
Employees	6	LT Debt/Eq	-	Earnings	Sep 03	SMA200	-72.21%	Avg Volume	1.46M	Price	1.67
IPO	Mar 09, 2022	Option/Short	No / Yes	EPS/Sales Surpr.	0.00% -	Trades		Volume	74,615,592	Change	9.87%

Jan-15-26 07:00AM	Abpro's Lead Program ABP-102 Featured in Celltrion Presentation at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -8.60%
Jan-06-26 07:00AM	Abpro and Celltrion, Inc. Announce U.S. FDA IND Clearance for Lead Multispecific Antibody Cancer Candidate ABP-102 / CT-P72 (GlobeNewswire) +19.75%
Dec-15-25 07:00AM	Abpro Holdings Announces Submission of an IND Application to Initiate a Phase 1 Clinical Trial of T cell engager ABP-102/CT-P72 for HER2-positive Cancers (GlobeNewswire)
Dec-09-25 07:00AM	Abpro Granted Nasdaq Listing Extension to Pursue Compliance and Strategic Objectives (GlobeNewswire) +6.26%
Nov-04-25 09:15AM	Abpro and Celltrion to Present Preclinical Data for CT-P72/ABP-102 at SITC 2025, Highlighting a Next-Generation HER2xCD3 T-Cell Engager (GlobeNewswire)
07:00AM	Loading…
Nov-03-25 07:00AM	Abpro Announces 1-for-30 Reverse Stock Split Effective November 3, 2025 (GlobeNewswire)
Aug-05-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +15.81%
Jul-28-25 10:30AM	BC-Most Active Stocks (Associated Press Finance)
Jul-25-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +18.53%
Jul-17-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) -10.08%
Apr-27-25 02:00PM	Abpro and Celltrion Unveil Preclinical Data for ABP-102/CT-P72 at AACR 2025, Showcasing Potential Best-in-Class HER2 x CD3 T-Cell Engager (GlobeNewswire)
Mar-25-25 04:30PM	Abpro Announces Oral Presentation of First Preclinical Data for ABP-102/CT-P72, a Tetravalent Bispecific HER2 x CD3 T-Cell Engager, at AACR Annual Meeting 2025 (GlobeNewswire) -9.45%
Mar-10-25 06:34PM	Abpro Statement on the Departure of Former CEO Ian Chan (GlobeNewswire) -5.10%
Dec-12-24 04:05PM	Abpro Holdings Celebrates Closing of Business Combination with Nasdaq Bell Ringing (GlobeNewswire)
Jun-13-24 04:15PM	Atlantic Coastal Acquisition Corp. II Receives Notification of Deficiency from Nasdaq Related to Delayed Quarterly Report on Form 10-Q (PR Newswire)
08:00AM	Loading…
Jan-22-24 08:00AM	Abpro Announces Filing of Registration Statement on Form S-4 in Connection with Business Combination Agreement with Atlantic Coastal Acquisition Corp. II (GlobeNewswire)
Oct-18-23 04:15PM	Atlantic Coastal Acquisition Corp. II Announces Extension of Business Combination Period and Additional Contribution to Trust Account (PR Newswire)
Sep-06-23 08:11AM	IMPORTANT: Atlantic Coastal Acquisition Corp. Files Definitive Proxy Statement in Connection with Plan to Extend the Amount of Time the Company has to Consummate a Business Combination (PR Newswire)
Aug-25-23 04:11PM	Atlantic Coastal Acquisition Corp. Announces Plans to Extend Deadline to Complete Initial Business Combination. (PR Newswire)
Aug-18-23 04:11PM	Atlantic Coastal Acquisition Corp. Will Redeem Its Public Shares and Will Not Consummate an Initial Business Combination (PR Newswire)
May-30-23 05:00PM	Atlantic Coastal Acquisition Corp. Receives Notification of Deficiency from Nasdaq Related to Delayed Quarterly Report on Form 10-Q (PR Newswire)

Abpro Holdings, Inc. operates as a capital pool company. The company was founded in 2004 and is headquartered in Woburn, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Suk Jin Wook (Miles)	CEO and Chairman	Jul 31 '25	Buy	0.28	72,035	20,170	718,512	Aug 04 05:22 PM
Suk Jin Wook (Miles)	CEO and Chairman	May 19 '25	Buy	0.26	16,200	4,212	146,477	May 19 08:37 PM
Suk Jin Wook (Miles)	CEO and Chairman	Apr 29 '25	Buy	0.25	4,325	1,081	130,277	May 01 04:21 PM
Suk Jin Wook (Miles)	CEO and Chairman	Apr 24 '25	Buy	0.34	26,542	9,024	125,902	Apr 25 04:58 PM
Suk Jin Wook (Miles)	CEO and Chairman	Apr 23 '25	Buy	0.28	7,460	2,089	99,360	Apr 25 04:58 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ABP

Abpro Holdings Inc

Upgrade your FINVIZ experience